Roche is set to introduce its three next-generation SARS-CoV-2 rapid antigen tests (‘2.0’) for self-test and professional use in countries that accept the CE Mark.

The tests include the SARS-CoV-2 Rapid Antigen Test 2.0, the SARS-CoV-2 Rapid Antigen Test 2.0 Nasal for professional use, and the SARS-CoV-2 Antigen Self Test Nasal for self-test.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

They feature improved performance, with the addition of new digital data sharing capabilities and an enhanced capture antibody.

The new SARS-CoV-2 rapid antigen tests (‘2.0’) use nasopharyngeal and nasal swab samples, respectively, and provide results in 15 minutes.

This aids in a SARS-CoV-2 infection diagnosis in people with or without symptoms.

The company stated that all the three tests have the capability to detect major variants of concern, including Delta and Omicron variants.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Roche Diagnostics CEO Thomas Schinecker said: “The continued evolution of the SARS-CoV-2 virus and Covid-19 pandemic reinforce the need for individuals and healthcare systems to have access to the most reliable rapid testing solutions possible.

“As a leader in diagnostic innovation, we are proud to be one of the first among our industry to apply insights gained from the past two years toward a next-generation rapid test portfolio.

“These tests are ready to support global society as we navigate this next phase of the pandemic.”

They join the company’s broad Covid-19 portfolio that includes various serological, molecular, and digital solutions.

These solutions help in diagnosing and managing the disease in the initial stages of infection, during the recovery phase, and after the resolution of infection.

Roche intends to start distribution of the new rapid test portfolio in the coming weeks.